{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:52:23Z","timestamp":1787849543891,"version":"build-2784847793"},"reference-count":40,"publisher":"BMJ","issue":"12","funder":[{"name":"The Youth Scientific Research Training Project of GZUCM","award":["2019QNPY02"],"award-info":[{"award-number":["2019QNPY02"]}]},{"name":"The Key Laboratory Program of Universities in Guangdong Province","award":["2018KSYS006"],"award-info":[{"award-number":["2018KSYS006"]}]},{"name":"The Key Program of the First-Class Discipline of Guangzhou University of Chinese Medicine","award":["XK2018001"],"award-info":[{"award-number":["XK2018001"]}]},{"name":"The Young Top Talent Project of Scientific and Technological Innovation in Special Support Plan for Training High-level Talents in Guangdong","award":["2017TQ04R627"],"award-info":[{"award-number":["2017TQ04R627"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873375"],"award-info":[{"award-number":["81873375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81904275"],"award-info":[{"award-number":["81904275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2020,7,8]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To assess the efficacy and safety of A\u03b2-targeting agents for mild to moderate Alzheimer\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The MEDLINE, Embase, Cochrane Central Register of Controlled Trials, PsycINFO, ClinicalTrials.gov and the WHO\u2019s International Clinical Trials Registry Platform search portal were searched from their inception to April 2020. We generated pooled estimates using random effects meta-analyses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>\nNineteen randomised controlled trials, of which 17 had a low risk of bias, included 12\u2009903 participants. The meta-analysis showed no difference in the cognitive subscale of Alzheimer\u2019s Disease Assessment Scale (ADAS-Cog) between anti-A\u03b2 drugs and placebo (mean difference (MD): 0.20, 95%\u2009CI \u22120.40 to 0.81;\n<jats:italic>I<\/jats:italic>\n<jats:sup>2<\/jats:sup>\n=99.8%; minimal important difference 3.1\u20133.8 points, moderate-certainty evidence). For ADAS-Cog, results suggested that one drug that increases A\u03b2 clearance may differ in effect (MD: \u22120.96, 95%\u2009CI \u22120.99 to \u22120.92) from drugs that reduce A\u03b2 production (MD: 0.78, 95%\u2009CI 0.25 to 1.32) (interaction p&lt;0.000001); this difference also existed in the outcome of MMSE and CDR-SOB. Compared with placebo, anti-A\u03b2 drug-related adverse events were as follows: anxiety, depression, diarrhoea, fatigue, rash, syncope and vomit.\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>From current evidence, anti-A\u03b2 interventions are unlikely to have an important impact on slowing cognitive or functional decline. Although the subgroup analysis suggested possible benefits from A\u03b2 clearance drugs, the analysis has limited credibility, and a benefit from drugs that increase clearance, if real, is very small.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>PROSPERO registration number CRD42019126272.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/jnnp-2020-323497","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T21:25:56Z","timestamp":1602537956000},"page":"1316-1324","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Anti-A\u03b2 agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis"],"prefix":"10.1136","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-4699","authenticated-orcid":false,"given":"Liming","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaolei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenggui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"2024120316350539000_91.12.1316.1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006189"},{"key":"2024120316350539000_91.12.1316.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.6669"},{"key":"2024120316350539000_91.12.1316.3","first-page":"10","article-title":"Active A\u03b2 immunotherapy CAD106 in Alzheimer's disease: a phase 2B study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2024120316350539000_91.12.1316.4","first-page":"195","article-title":"Alzheimer's disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2024120316350539000_91.12.1316.5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/molecules22101692","article-title":"\u03b2-Amyloid and the Pathomechanisms of Alzheimer\u2019s Disease: A Comprehensive View","volume":"22","author":"Penke","year":"2017","journal-title":"Molecules"},{"key":"2024120316350539000_91.12.1316.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-017-2463-7"},{"key":"2024120316350539000_91.12.1316.7","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bph.14593","article-title":"Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy","volume":"176","author":"Nalivaeva","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2024120316350539000_91.12.1316.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(01)00010-9"},{"key":"2024120316350539000_91.12.1316.9","doi-asserted-by":"publisher","DOI":"10.1093\/embo-reports\/kvf124"},{"key":"2024120316350539000_91.12.1316.10","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0394fje"},{"key":"2024120316350539000_91.12.1316.11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311652200"},{"key":"2024120316350539000_91.12.1316.12","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"key":"2024120316350539000_91.12.1316.13","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1697-05.2005"},{"key":"2024120316350539000_91.12.1316.14","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159740.16984.3C"},{"key":"2024120316350539000_91.12.1316.15","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.90"},{"key":"2024120316350539000_91.12.1316.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70043-0"},{"key":"2024120316350539000_91.12.1316.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210951"},{"key":"2024120316350539000_91.12.1316.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706441"},{"key":"2024120316350539000_91.12.1316.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1866"},{"key":"2024120316350539000_91.12.1316.20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fnagi.2018.00100","article-title":"Targeting beta-amyloid at the CSF: a new therapeutic strategy in Alzheimer's disease","volume":"10","author":"Menendez-Gonzalez","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"2024120316350539000_91.12.1316.21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/14737175.2019.1620106","article-title":"Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease: a systematic review with meta-analysis","volume":"19","author":"Liu","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"2024120316350539000_91.12.1316.22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/acn3.469","article-title":"Efficacy and safety of anti-amyloid-\u03b2 immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis","volume":"4","author":"Mo","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"2024120316350539000_91.12.1316.23","unstructured":"ClinicalTrials.gov . USNIoH, 2019. Available: https:\/\/clinicaltrials.gov\/ct2\/results?cond=early+ALZHEIMER+&term=&cntry=&state=&city=&dis"},{"key":"2024120316350539000_91.12.1316.24","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2607"},{"key":"2024120316350539000_91.12.1316.25","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300881"},{"key":"2024120316350539000_91.12.1316.26","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-37"},{"key":"2024120316350539000_91.12.1316.27","doi-asserted-by":"crossref","unstructured":"Bjelakovic G , Gluud LL , Nikolova D , et al . Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev 2014;366.doi:10.1002\/14651858.CD007469.pub2","DOI":"10.1002\/14651858.CD007469.pub2"},{"key":"2024120316350539000_91.12.1316.28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s13054-015-1133-0","article-title":"The effect of mild induced hypothermia on outcomes of patients after cardiac arrest: a systematic review and meta-analysis of randomised controlled trials","volume":"19","author":"Zhang","year":"2015","journal-title":"Crit Care"},{"key":"2024120316350539000_91.12.1316.29","unstructured":"GSe HJPT . Cochrane Handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011."},{"key":"2024120316350539000_91.12.1316.30","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Green S . Cochrane Handbook for systematic reviews of interventions, 2008.","DOI":"10.1002\/9780470712184"},{"key":"2024120316350539000_91.12.1316.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c117"},{"key":"2024120316350539000_91.12.1316.32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/jrsm.1095","article-title":"Meta-Regression approximations to reduce publication selection bias","volume":"5","author":"Stanley","year":"2014","journal-title":"Res Synth Methods"},{"key":"2024120316350539000_91.12.1316.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-014-1196-3"},{"key":"2024120316350539000_91.12.1316.34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jclinepi.2019.02.003","article-title":"Grade guidelines: 22. The grade approach for tests and strategies-from test accuracy to patient-important outcomes and recommendations","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"2024120316350539000_91.12.1316.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c67808"},{"key":"2024120316350539000_91.12.1316.36","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology"},{"key":"2024120316350539000_91.12.1316.37","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159740.16984.3C"},{"key":"2024120316350539000_91.12.1316.38","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00702-008-0136-2","article-title":"Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial","volume":"115","author":"Kessler","year":"2008","journal-title":"J Neural Transm"},{"key":"2024120316350539000_91.12.1316.39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001017"},{"key":"2024120316350539000_91.12.1316.40","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70014-0"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2020-323497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T16:27:42Z","timestamp":1733416062000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-323497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,11,16]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/jnnp-2020-323497"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2020-323497","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]}}}